Celera and Abbott form genetic research collaboration

A key aim of the collaboration is to investigate if genetic variants Celera has identified can predict how patients may respond to treatment. The identification of treatment response markers may assist in further development of the drug.

Under the terms of this collaboration, Abbott will pay Celera an undisclosed fee to perform this study and any resulting companion diagnostic product could be developed by Celera and commercialized through its existing strategic alliance with Abbott.

Thomas White, chief scientific officer of Celera, said: “We’re pleased to enter this collaboration with Abbott as it further reinforces Celera’s commitment to personalized medicine.

“The results of this study will provide new information on the correlation between genetic markers associated with disease and response to therapy. Routinely testing this general concept in early clinical trials may give us new and important insights to personalizing disease management.”